study / researchyánjiū研究to show / to indicatexiǎnshì显示，GLP-1 receptor agonist drug classGLP-1GLP-1drug / medicationyàowù药物may possibly / mighthuò kě或可to reduce / to lowerjiàngdī降低depressionyìyù抑郁andhé和anxietyjiāolǜ焦虑worseningèhuà恶化riskfēngxiǎn风险。
study / research
yánjiū
研究
to show / to indicate
xiǎnshì
显示
GLP-1 receptor agonist drug class
GLP-1
GLP-1
drug / medication
yàowù
药物
may possibly / might
huò kě
或可
to reduce / to lower
jiàngdī
降低
depression
yìyù
抑郁
and
hé
和
anxiety
jiāolǜ
焦虑
worsening
èhuà
恶化
risk
fēngxiǎn
风险
one (study)
yī xiàng
一项
published in
fābiǎo zài
发表在
The Lancet Psychiatry journal
Liǔyèdāo Jīngshén Bìngxué
柳叶刀·精神病学
structural particle
de
的
study
yánjiū
研究
to find / to discover
fāxiàn
发现
GLP-1 receptor agonist drug class
GLP-1
GLP-1
type / class of
lèi
类
drug / medication
yàowù
药物
with / and
yǔ
与
psychiatric care
jīngshēnkē
精神科
to seek medical care
jiùzhěn
就诊
number of visits
cìshù
次数
to decrease
jiǎnshǎo
减少
42 percent
bǎifēnzhī sìshí èr
42%
to be associated with
xiāngguān
相关
researchers
yánjiū rényuán
研究人员
to analyze
fēnxī
分析
completion particle
le
了
Sweden
Ruìdiǎn
瑞典
nearly
jìn
近
nearly 100,000 (people)
shí wàn míng
十万名
patient
huànzhě
患者
structural particle
de
的
data
shùjù
数据